LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's (NOVOb.CO) , opens new tab Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the ...
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
Efterspørgslen efter Ozempic og Wegovy tog et ryk opad i sidste uge, og Bank of America ser nu mulighed for en opjustering ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
Not only has the Danish economy benefited from the success of Ozempic and Wegovy, two more weight-management medications ...
Der er fuld fart på salget af Novo Nordisk guldæg - fedmemidlet Wegovy - i USA. Således er de amerikanske læger gået fra at udskrive 5.000 startpakker til Wegovy ved årets start til omkring 40.000 i ...